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OBJECTIVE—Monocytes in childhood-onset type 1 diabetes
show distinct gene expression. We hypothesize that monocyte
activation in monozygotic (MZ) twin pairs discordant for child-
hood-onset type 1 diabetes could reﬂect distinct stages of the
disease process including diabetes susceptibility (differences
between twins, both diabetic and nondiabetic, and control sub-
jects) and/or disease progression (differences between diabetic
and nondiabetic twins).
RESEARCH DESIGN AND METHODS—We studied patterns
of inﬂammatory gene expression in peripheral blood monocytes
of MZ twin pairs (n  10 pairs) discordant for childhood-onset
type 1 diabetes, normal control twin pairs (n  10 pairs), and
healthy control subjects (n  51) using quantitative-PCR (Q-
PCR). We tested the 24 genes previously observed by whole
genome analyses and veriﬁed by Q-PCR in autoimmune diabetes
and performed a hierarchical cluster analysis.
RESULTS—Of 24 genes abnormally expressed in childhood-
onset type 1 diabetes, we revalidated abnormal expression in 16
of them in diabetic twins including distinct sets of downregulated
(P  0.03) and upregulated (P  0.02) genes. Of these 16 genes,
13 were abnormally expressed in nondiabetic twins, implicating
these genes in diabetes susceptibility (P  0.044 for all). Cluster
analysis of monocyte gene-expression in nondiabetic twins iden-
tiﬁed two distinct, mutually exclusive clusters, while diabetic
twins had a network of positively correlated genes.
CONCLUSIONS—Patients with childhood-onset type 1 diabetes
show abnormal monocyte gene–expression levels with an al-
tered gene–expression network due to gene-environment inter-
action. Importantly, perturbed gene–expression clusters were
also detected in nondiabetic twins, implicating monocyte abnor-
malities in susceptibility to diabetes. Diabetes 59:1751–1755,
2010
T
he destructive autoimmune process associated
with type 1 diabetes involves both the innate
and adaptive immune response represented by
monocytes, dendritic cells, macrophages, and
T-cells, which inﬁltrate the islets at disease onset (1).
Patients with type 1 diabetes show functional abnormalities
of monocytes and monocyte-derived cells (2–8), which are
assumed to promote the immunogenic potential of the cells.
Recently, we reported that type 1 diabetic patients show
abnormal monocyte gene–expression proﬁles involving 24
inﬂammatory-related genes (5). Two distinct sets of cor-
relating genes were found. One cluster consisted of down-
regulation of 12 core inﬂammatory cytokine/compound
genes strongly correlated to the expression of PDE4B (the
PDE4B-associated cluster). A second cluster was most
prevalent in childhood-onset type 1 diabetes and consisted
of 10 upregulated genes strongly correlated to the expres-
sion of FABP5 (the FABP5-associated cluster).
These aberrant expression proﬁles in monocytes could
be either familial, through shared genetic and/or environ-
mental factors, or disease-associated. To resolve this
issue, we studied monocytes of monozygotic (MZ) twin
pairs discordant for childhood-onset type 1 diabetes, i.e.,
one twin had type 1 diabetes and the other did not.
Gene-expression abnormalities associated with type 1
diabetes susceptibility would be found in both type 1
diabetic twins and their nondiabetic twins (such similari-
ties between MZ twins being due to shared genes, shared
environment, or both), but not in normal healthy individ-
uals (twin pair case–control design). Changes associated
with type 1 diabetes progression would only be found in
the type 1 diabetic twin (co-twin case–control design).
RESEARCH DESIGN AND METHODS
Twins and control subjects. MZ twin pairs were selected from the British
Diabetic Twin Study (9). Of 451 twin pairs, we selected MZ pairs discordant
for type 1 diabetes and eligible according to the following criteria: 1)
European origin, 2) affected twins had type 1 diabetes (diagnosed according
to American Diabetes Association guidelines), 3) both twins of each pair were
available for study, 4) neither twin was receiving drugs other than human
insulin in the index case, and 5) the nondiabetic twin had a low disease risk,
which is a risk less than 2% based on the lack of diabetes-associated
antibodies (9,10). Of the selected 10 MZ pairs discordant for type 1 diabetes
(n  10, mean age 32 years, range 18–50 years, three males), the diabetic
twins were treated with insulin from the time of diagnosis and were taking
highly puriﬁed human insulin at least twice daily (means [ SD] duration of
diabetes 22 years [11] in the diabetic twin). Monozygosity was established in
twin pairs using both clinical data and at least 22 blood groups as described
previously (9,10). Control MZ twin pairs (n  12, mean age 37 years [11], range
17–53 years, four males) were recruited from the local population through
advertising. Childhood-onset type 1 diabetes singletons (n  30, mean age 24
years, range 5–50 years, 11 males) were identiﬁed from our previous study (5).
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males) were recruited from enrolling laboratory staff, medical staff, and
medical students. The inclusion criteria for the healthy controls were no
family history of diabetes or other autoimmune disease; no illness at the time
of testing or for at least two weeks prior to the blood withdrawal including
acute infections and allergic reactions; taking no drugs; and on a normal diet.
All the subjects gave informed consent. The ethics committees of Bart’s and
The London National Health Service Trust and Royal Hospital Trusts, Hein-
rich-Heine University Du ¨sseldorf, and the Erasmus MC Medical Centre
Rotterdam approved the study.
Blood collection and monocyte isolation. Peripheral blood mononuclear
cells (PBMCs) were isolated from heparinized blood by the standard Ficoll
procedure (11). Puriﬁed PBMCs were then frozen in 10% DMSO and stored in
liquid nitrogen. This enabled us to store the samples in order to batch samples
for assays. CD14 monocytes were isolated by positive selection as described
from frozen PBMCs using a magnetic cell sorting system (Miltenyi Biotec,
U.K.); monocyte purity was 95% (determined by morphological screening
after trypan blue staining and ﬂuorescence-activated cell sorter).
Quantitative RT–PCR. In this present study, RNA was isolated from
monocytes using RNeasy columns (Qiagen, Hilden, Germany), and both this
method and quantitative RT-PCR has been described in detail elsewhere (11).
Genes under study are the sets of genes previously described as aberrantly
expressed in type 1 and type 2 diabetes. All Taqman probes and consensus
primers were preformulated and custom designed by Applied Biosystems
(Supplemental Table 1). PCR ampliﬁcation of the housekeeping gene ABL
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FIG. 1. This ﬁgure shows monocyte gene–expression levels from diabetic index twins, nondiabetic co-twins, and the index twin of a healthy control
(HC) twin pair. Fold changes (analyzed as in Table 1) are presented similarly with increased (red) or decreased (green) expression levels (the color
intensities code for the strength of the expression levels). A gray line separates two distinct gene–expression proﬁles (PDE4B- and FABP5-associated
clusters). For the majority, diabetic and nondiabetic twins show similar increased or decreased gene–expression levels compared with HC twins. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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Table 1 in the online appendix available at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-1433/DC1. The quantitative value obtained from
Q-PCR is a cycle threshold (CT). The fold change values between different
groups were determined from the normalized CT values (CT gene  CT
housekeeping gene).
Statistical analysis. Data were assembled using Microsoft Excel software
and are expressed as means ( SD). Data were analyzed using SPSS/the Prism
statistical package (SPSS 15.0 for Windows/GraphPad Prism, version 3). Data
were tested for normal distribution using the Kolmogorov-Smirnov test.
Hierarchical gene analysis and heat maps were determined using a Pearson
correlation matrix. Depending on the distribution pattern and the total
number of subjects, parametric (normal distribution and 50 subjects) or
nonparametric tests (skewed distribution or 50 subjects) were used. Levels
of signiﬁcance were set at P  0.05 (two-tailed).
RESULTS
Q-PCR analysis. A preliminary observation and valida-
tion study identiﬁed 24 genes abnormally expressed in
monocytes from type 1 diabetic patients (5). These 24
genes were examined in this revalidation study of MZ
twins and the gene expression levels of 16 of these 24
monocyte genes were abnormally expressed in twins with
childhood-onset type 1 diabetes when compared with 12
normal MZ twin pairs and 51 normal singletons (Fig. 1)
(Table 1). These 16 abnormally expressed genes were
PDE4B, IL-1B, PTGS2, BCL2A1, TNFAIP3, TNF, CXCL2,
HSP1A (all downregulated) (P  0.04 for all) and CCL2,
CCL7, STX1A, EMP1, PTPN7, CD9, FABP5, DHRS3 (all
upregulated) (P  0.02 for all) (Fig. 1) (Table 1).
To determine whether the changes were familial, i.e.,
due to gene-environment interaction independent of dia-
betes and hyperglycemia, we examined the nondiabetic
MZ twins of these patients, selected to be at low disease
risk. Of 16 genes that were altered in the validation study
in the index twins, 13 were also altered in the nondiabetic
twins compared with control subjects: PDE4B, IL-1B,
PTGS2, BCL2A1, TNFAIP3, TNF, CXCL2, HSP1A (all
downregulate) (P  0.04 for all) and CCL7, EMP1, PTPN7,
CD9, FABP5 (all upregulated) (P  0.044 for all) (Fig. 1)
(Fig. 1) (Table 1); 2 additional genes were abnormally
expressed in nondiabetic, but not diabetic, twins, i.e.,
DUSP2 and PTX3 (both downregulated, P  0.05 for each)
(Table 1). Only four genes (STX1A, CDC42, PTPN7, and
CD9) were abnormally expressed in diabetic twins com-
pared with both nondiabetic twins and control subjects
(P  0.041 for all), consistent with a diabetic effect.
These four genes are also abnormally expressed in
monocytes of type 2 diabetic patients, consistent with a
metabolic effect (5).
Cluster analysis. Diabetic twins had a similar gene-expres-
sion proﬁle and gene order in cluster analysis to that found
previously in childhood-onset type 1 diabetes singletons (Fig.
2A and C); strongly positively correlated genes clustered in
both diabetic groups with the dominant cluster extending
from CCL2 to NAB2 (Fig. 2A and C). Nondiabetic twins
showed similar abnormalities of gene expression (13 of 16)
(data not shown) and gene order to their diabetic twins and
a similar positively correlating dominant gene cluster (Fig.
2B); by contrast, the gene order differed from control twins
(data not shown), and the latter had no comparable domi-
nant cluster (Fig. 2D). Both diabetic twins and singletons had
two genes (PTGS2 and HSPA1A) strongly negatively corre-
lated with the dominant cluster (Fig. 2A and C); in the
nondiabetic twins, these negatively correlated genes ex-
tended into a cluster from PDE4B to CCL20 (Fig. 2B). The
two gene-expression clusters evident in the nondiabetic
twins broadly corresponded to the PDE4B-associated and
FABP5-associated gene clusters with the latter previously
reported by us as the major gene cluster in childhood-onset
TABLE 1
Q-PCR analysis of monocytes of MZ twins with and without type 1 diabetes and healthy control (HC) MZ twin pairs. The quantitative
values are expressed as fold changes; in essence, the quantitative value obtained from Q-PCR is a CT. The fold change values between
different groups were determined from normalized CT values as previously described (5). Data were standardized to 51 healthy
control singletons (used as the calibrator). Signiﬁcance was tested by ANCOVA so that values 1 (*) reﬂect higher expression and
1 (†) lower expression in twins than in these control singletons
Index diabetic twin Nondiabetic co-twin
fold change P value vs. HC fold change P value vs. HC P value vs. co-twin
PDE4B 0.29† 0.001 PDE4B 0.32† 0.001 0.741
CCL20 0.45 0.482 CCL20 0.27 0.129 0.425
DUSP2 0.74 0.067 DUSP2 0.44† 0.018 0.142
IL-1B 0.16† 0.001 IL-1B 0.12† 0.001 0.650
PTGS2 0.23† 0.014 PTGS2 0.25† 0.014 0.899
IL-6 1.99 0.448 IL-6 0.86 0.999 0.216
BCL2A1 0.42† 0.021 BCL2A1 0.29† 0.001 0.076
PTX3 0.66 0.129 PTX3 0.46† 0.027 0.360
ATF3 0.86 0.224 ATF3 1.00 0.697 0.654
TNFAIP3 0.54† 0.007 TNFAIP3 0.35† 0.001 0.266
NAB2 1.26 0.499 NAB2 1.75 0.601 0.569
TNF 0.35† 0.026 TNF 0.48† 0.039 0.561
CXCL2 0.41 0.035 CXCL2 0.29† 0.016 0.364
CCL7 75.58* 0.009 CCL7 43.71* 0.033 0.425
STX1A 13.83* 0.002 STX1A 9.00 0.081 0.019*
CCL2 14.83* 0.017 CCL2 8.94 0.074 0.380
EMP1 5.43* 0.001 EMP1 4.56* 0.007 0.544
CDC42 2.19 0.329 CDC42 1.60 0.754 0.015*
PTPN7 3.36* 0.004 PTPN7 2.22* 0.043 0.023*
MAPK6 1.75 0.106 MAPK6 0.77 0.218 0.082
DHRS3 6.11* 0.017 DHRS3 7.06 0.203 0.741
CD9 3.94* 0.005 CD9 2.81* 0.014 0.040*
HSP1A 0.28† 0.001 HSP1A 0.18† 0.001 0.108
FABP5 7.84* 0.001 FABP5 2.89* 0.002 0.064
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nondiabetic twins or diabetic singletons was found in control
twins. Importantly, the disease discordant twin pairs showed
signiﬁcant correlations for 12 of 16 abnormally expressed
genes (r [range] 0.68–0.95; P  0.05 for all 12) (data not
shown), which was consistent with a strong shared gene-
environment interaction.
DISCUSSION
We previously reported that monocyte gene–expression
proﬁles are abnormal in type 1 diabetes and vary accord-
ing to age at diabetes onset, suggesting heterogeneity in
disease pathogenesis (5). We revalidated abnormal mono-
cyte gene–expression levels for 16 genes in twins with
FIG. 2. This ﬁgure shows a heat map of correlations between gene-expression levels for 24 genes initially observed to be abnormally expressed
in type 1 diabetes in: index diabetic twins (A), their nondiabetic co-twins (B), diabetic singletons (C), and healthy control twins (D). Correlations
in gene-expression level are presented as positive (blue) or negative (red) expression levels (the color intensities code for the strength of the
correlations). The hierarchy of gene expression (found in cluster analysis) in all ﬁgures is ordered according to that in the index diabetic twins;
two distinct clusters are noted in nondiabetic co-twins. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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that the gene order was similar in both twins and single-
tons with childhood-onset type 1 diabetes, but was distinct
from that found in control twins and singletons. Diabetic
twins and singletons showed a dominant cluster of 12
abnormally expressed monocytes genes, including FABP5.
Our failure to revalidate all the abnormally expressed
monocyte genes initially reported could be due to the
relatively small numbers of highly selected twin pairs,
including selection of only childhood-onset type 1 diabetic
patients, which will have limited the study power.
The present observations in type 1 diabetes indicate that
much of the altered monocyte gene–expression proﬁle is
due to shared gene-environment interaction since similar
changes were detected in their genetically identical twins
who were not diabetic and selected to be at low disease
risk. Such similarities between MZ twins are not necessar-
ily due to shared genes as shared environmental effects or
shared gene/environment interaction would give the
same result. Changes in these nondiabetic twins likely
reﬂect monocyte changes associated with disease sus-
ceptibility without necessarily predicting type 1 diabe-
tes. Of 16 monocyte genes abnormally expressed in type
1 diabetic twins, 13 were abnormal in their nondiabetic
twins and gene-expression levels for the majority were
strongly correlated between diabetic and nondiabetic
twins. Moreover, in contrast to control subjects, the gene
order and dominant gene cluster on cluster analysis were
broadly similar in co-twins. It follows from our observa-
tions that most abnormalities in monocyte gene expres-
sion in childhood-onset type 1 diabetes are associated with
familial predisposition to the disease, consistent with a
previous study of monocyte responses in disease-discor-
dant twins (7). Resolution of the degree of genetic contri-
bution to altered monocyte gene expression must await a
classic twin study; but this would require substantially
more MZ twins discordant for type 1 diabetes—as well as
matched dizygotic twins—than we studied.
Cluster analysis showed a striking disparity between non-
diabetic twins and other groups in that they had two clear
gene–expression clusters and one cluster negatively corre-
lated with the other. The dominant monocyte gene–expres-
sion cluster, with an upregulated FABP5, included genes
involved in adhesion, chemotactic, and metabolic factors,
while the less prominent negatively correlated and down-
regulated PDE4B-associated cluster involved proinﬂamma-
tory cytokines and chemokines (5). These two gene clusters
were perturbed in the diabetic twins into a network of
predominantly positively correlated genes with a weaker
downregulation of the PDE4B-associated gene cluster, po-
tentially representing a progression marker to clinically overt
type 1 diabetes. Longitudinal studies of at-risk individuals
could clarify if such changes reﬂect disease progression.
Our aberrant gene–expression data implicate altered
monocyte function in the pathogenesis of childhood-onset
type 1 diabetes through gene-environment interaction. The
character of the genes and previous studies (6,7,12) sug-
gest that these functional changes include altered mono-
cyte integrin expression, adhesion to endothelial cells and
ﬁbronectin, lipid raft and immune synapse formation, cell
motility and assembly, and induction of proinﬂammatory
cells. In-depth functional studies using transfection or
small interfering RNA regulating the expression of se-
lected key genes in human monocytes will need to be
performed to deﬁne their exact function in diabetes patho-
genesis. A substantially expanded classic twin study, also
using dizygotic twins, would be required to determine to
what extent genetic factors alone determine the altered
gene expression. Nevertheless, identiﬁcation of key mono-
cyte genes involved in the perturbed gene–expression
networks predisposing to type 1 diabetes suggests possi-
ble therapeutic targets to prevent progression to clinical
disease.
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